Yuan Zhi
Stock Analyst at B. Riley Securities
(4.54)
# 1,032
Out of 4,655 analysts
135
Total ratings
44.4%
Success rate
22.1%
Average return
Main Sectors:
Stocks Rated by Yuan Zhi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LNTH Lantheus Holdings | Downgraded: Hold | $129 → $105 | $100.91 | +4.45% | 28 | Aug 17, 2026 | |
| HYPR Hyperfine | Maintained: Buy | $2 → $1.6 | $0.8958 | +78.61% | 9 | Aug 10, 2026 | |
| STLN Starling Oncology | Maintained: Buy | $6 → $11 | $6.31 | +74.33% | 3 | Aug 7, 2026 | |
| MIR Mirion Technologies | Maintained: Buy | $29 | $15.74 | +84.24% | 11 | Jul 30, 2026 | |
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $44 | $13.55 | +224.72% | 1 | Jul 22, 2026 | |
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $10 | $4.64 | +115.52% | 1 | Jun 25, 2026 | |
| TNGX Tango Therapeutics | Rated: Buy | $21 → $35 | $25.29 | +38.39% | 7 | Jun 9, 2026 | |
| RDNT RadNet | Rated: Buy | $87 → $83 | $75.93 | +9.31% | 6 | May 1, 2026 | |
| SRTA Strata Critical Medical | Initiated Coverage: Buy | $8 | $5.90 | +35.59% | 1 | Mar 25, 2026 | |
| CATX Perspective Therapeutics | Rated: Buy | $11 → $13 | $3.22 | +303.73% | 13 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $6.74 | +48.37% | 2 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 → $16 | $2.67 | +499.25% | 6 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $3 | $0.3772 | n/a | 3 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $2 | $1.05 | n/a | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $19 → $15 | $15.32 | n/a | 14 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $33.58 | n/a | 12 | Feb 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $34 | $35.45 | n/a | 5 | Jan 9, 2023 |
Lantheus Holdings
Aug 17, 2026
Downgraded: Hold
Price Target: $129 → $105
Current: $100.91
Upside: +4.45%
Hyperfine
Aug 10, 2026
Maintained: Buy
Price Target: $2 → $1.6
Current: $0.8958
Upside: +78.61%
Starling Oncology
Aug 7, 2026
Maintained: Buy
Price Target: $6 → $11
Current: $6.31
Upside: +74.33%
Mirion Technologies
Jul 30, 2026
Maintained: Buy
Price Target: $29
Current: $15.74
Upside: +84.24%
Lyell Immunopharma
Jul 22, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $13.55
Upside: +224.72%
Whitehawk Therapeutics
Jun 25, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $4.64
Upside: +115.52%
Tango Therapeutics
Jun 9, 2026
Rated: Buy
Price Target: $21 → $35
Current: $25.29
Upside: +38.39%
RadNet
May 1, 2026
Rated: Buy
Price Target: $87 → $83
Current: $75.93
Upside: +9.31%
Strata Critical Medical
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $5.90
Upside: +35.59%
Perspective Therapeutics
Mar 18, 2026
Rated: Buy
Price Target: $11 → $13
Current: $3.22
Upside: +303.73%
Dec 17, 2025
Maintained: Buy
Price Target: $10
Current: $6.74
Upside: +48.37%
Dec 16, 2025
Maintained: Buy
Price Target: $13 → $16
Current: $2.67
Upside: +499.25%
Oct 2, 2024
Reiterated: Buy
Price Target: $4 → $3
Current: $0.3772
Upside: n/a
Aug 7, 2024
Downgraded: Hold
Price Target: $16 → $2
Current: $1.05
Upside: n/a
Jul 30, 2024
Upgraded: Buy
Price Target: $19 → $15
Current: $15.32
Upside: n/a
Feb 7, 2024
Reiterated: Buy
Price Target: $79
Current: $33.58
Upside: n/a
Jan 9, 2023
Maintained: Buy
Price Target: $34
Current: $35.45
Upside: n/a